- Email: [email protected]
PET-FDG Versus CT in the Staging and Detection of Relapse in Patients with Hodgkin’s Disease or Non-Hodgkin Lymphoma
PII S1095-0397(98)00038-7
Clinical Positron Imaging Vol. 1, No. 4, 248. 1998 Copyright 1999 Elsevier Science Inc. Printed in the USA. All rights reserved. 1095-0397/98 $19.00
ABSTRACT
PET-FDG Versus CT in the Staging and Detection of Relapse in Patients with Hodgkin’s Disease or Non-Hodgkin Lymphoma: Two Years Experience J.A. Richter, M.J. Garcı´a-Velloso, C. Pe´rez-Equiza,1 C. Ga´mez, J. Pe´rez-Calvo,2 A. Gorosquieta,1 A. Crespo Departments of Nuclear Medicine-PET, Haematology1 and Oncology2, Clı´nica Universitaria and Hospital of Navarra, Pamplona, Spain
Purpose: To retrospectively evaluate the effectiveness of FDG-PET and CT in the staging and in the detection of residual disease or recurrence in patients with Hodgkin’s disease (HD) or Non-Hodgkin lymphoma (NHL). Materials and Methods: 63 whole body FDG-PET and 60 CT scans were performed in 21 patients with HD (10f/11m) and 42 with NHL (23f/19m). Seventeen evaluations were pretherapeutic. PET and CT scans were validated by histology (n 5 18) or clinical follow-up (n 5 45). Results: In 17 patients undergoing initial staging FDG-PET was true positive in 16 patients and true negative in one. A pathological CT scan, however, was found in only 13 patients and 3 studies were inconclusive. In 46 studies performed after treatment PET was true positive in 18/20 (S 5 90%) and true negative in 26/26 (E 5 100%), whereas CT was true positive in 5/6, true negative in 7/11, there were 27 inconclusive residual mass, a false positive and 4 false negative scans. Conclusion: FDG-PET may provide a more accurate means of staging and detecting relapse than CT in patients with Hodgkin’s disease or Non-Hodgkin lymphoma. (Clin Pos Imag 1998;1:248) 1999 Elsevier Science Inc.
248
Clinical Positron Imaging Vol. 1, No. 4, 248. 1998 Copyright 1999 Elsevier Science Inc. Printed in the USA. All rights reserved. 1095-0397/98 $19.00
ABSTRACT
PET-FDG Versus CT in the Staging and Detection of Relapse in Patients with Hodgkin’s Disease or Non-Hodgkin Lymphoma: Two Years Experience J.A. Richter, M.J. Garcı´a-Velloso, C. Pe´rez-Equiza,1 C. Ga´mez, J. Pe´rez-Calvo,2 A. Gorosquieta,1 A. Crespo Departments of Nuclear Medicine-PET, Haematology1 and Oncology2, Clı´nica Universitaria and Hospital of Navarra, Pamplona, Spain
Purpose: To retrospectively evaluate the effectiveness of FDG-PET and CT in the staging and in the detection of residual disease or recurrence in patients with Hodgkin’s disease (HD) or Non-Hodgkin lymphoma (NHL). Materials and Methods: 63 whole body FDG-PET and 60 CT scans were performed in 21 patients with HD (10f/11m) and 42 with NHL (23f/19m). Seventeen evaluations were pretherapeutic. PET and CT scans were validated by histology (n 5 18) or clinical follow-up (n 5 45). Results: In 17 patients undergoing initial staging FDG-PET was true positive in 16 patients and true negative in one. A pathological CT scan, however, was found in only 13 patients and 3 studies were inconclusive. In 46 studies performed after treatment PET was true positive in 18/20 (S 5 90%) and true negative in 26/26 (E 5 100%), whereas CT was true positive in 5/6, true negative in 7/11, there were 27 inconclusive residual mass, a false positive and 4 false negative scans. Conclusion: FDG-PET may provide a more accurate means of staging and detecting relapse than CT in patients with Hodgkin’s disease or Non-Hodgkin lymphoma. (Clin Pos Imag 1998;1:248) 1999 Elsevier Science Inc.
248